Cystatin C Assay Market worth $540 million by 2028

Comments · 132 Views

The global size of cystatin C assay market in terms of revenue was estimated to be worth USD 377 million in 2023 and is poised to reach USD 540 million by 2028, growing at a CAGR of 7.5% from 2023 to 2028.

The report "Cystatin C Assay Market by Product (Analyzers, Kits, Reagents), Method (ELISA, PETIA, IFA, CLIA, PENIA), Application (Diagnostics, Research), Sample Type (Blood, Urine), End User (Hospitals, Clinical Laboratories), Region- Global Forecast to 2028", is projected to reach USD 540 million by 2028 from USD 377 million in 2023, at a CAGR of 7.5% during the forecast period

Browse 215 market data Tables and 42 Figures spread through 271 Pages and in-depth TOC on "Cystatin C Assay Market by Product (Analyzers, Kits, Reagents), Method (ELISA, PETIA, IFA, CLIA, PENIA), Application (Diagnostics, Research), Sample Type (Blood, Urine), End User (Hospitals, Clinical Laboratories), Region- Global Forecast to 2028"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/cystatin-c-assay-market-186075328.html

The growth of this market is majorly driven by growing number of old age population and rising number of kidney diseases. However, high development costs of cystatin C assay may challenge the growth of this market.

UK in European cystatin C assay market to witness the highest shares during the forecast period.

The European cystatin C assay market is segmented into Germany, France, the UK, Italy, Spain, and the Rest of Europe. UK is projected to occupy the highest share during the forecast period. Market growth is attributed to the rising geriatric population chronic diseases, increasing number of accredited clinical hospital laboratories, growing government healthcare expenditure.

Clinical laboratories in End user’ cystatin C assay market to witness the second highest growth rate during the forecast period.

Based on the end user, cystatin C assay market is segmented into hospitals, clinical laboratories, and pharmaceutical biotechnology companies CROs academic research institutes The clinical laboratories registered the second highest CAGR, due to the growing number of clinical tests performed in laboratories and the increasing number of accredited laboratories, and serving as centralized hubs for diagnostic testing, where a wide array of tests, including cystatin C assays which support market growth.

China dominates the Asia Pacific cystatin C assay market.

The APAC cystatin C assay market is segmented into Japan, China, India, and Rest of Apac. In 2022, China accounted for the largest share of the Asian cystatin C assay market. The large share of China can be attributed to the government efforts to increase awareness about the early detection of diseases and regular health check-ups; rising healthcare expenditure; the increasing number of hospitals and clinical diagnostic laboratories in India and China; and strengthening research base for diagnostic procedures across India, China, and Japan, rising cases of CKD.

The significant players in the cystatin C assay are Siemens Healthcare GmbH (Germany), Thermo Fisher Scientific Inc. (US), Abbott (US), Roche Diagnostics Limited.(Switzerland), and Bio-Techne (US), Randox Laboratories Ltd. (UK), DiaSys Diagnostic Systems GmbH (Germany), and Eurolyser Diagnostica GmbH (Austria)

Don’t miss out on business opportunities in Cystatin C Assay Market. Speak to our analyst and gain crucial industry insights that will help your business grow.

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com

Comments